Document is current
Any future updates will be listed below
-
Authors
Wang, Haiping
Franco, Fabien
Tsui, Yao-Chen
Xie, Xin http://orcid.org/0000-0002-6784-4860
Trefny, Marcel P. http://orcid.org/0000-0001-6755-7899
Zappasodi, Roberta
Mohmood, Syed Raza
Fernández-García, Juan
Tsai, Chin-Hsien
Schulze, Isabell
Picard, Florence
Meylan, Etienne http://orcid.org/0000-0002-0899-2230
Silverstein, Roy
Goldberg, Ira
Fendt, Sarah-Maria http://orcid.org/0000-0001-6018-9296
Wolchok, Jedd D. http://orcid.org/0000-0001-6718-2222
Merghoub, Taha http://orcid.org/0000-0002-1518-5111
Jandus, Camilla http://orcid.org/0000-0002-7405-5747
Zippelius, Alfred
Ho, Ping-Chih http://orcid.org/0000-0003-3078-3774
- License Information
-
More Information
Article History
Received: 24 July 2019
Accepted: 19 December 2019
First Online: 17 February 2020
Competing interests
: H.W. and P.-C.H. are inventors on a patent application related to targeting CD36 in cancer immunotherapy. P.-C.H. is serving as a member of the scientific advisory board for Elixiron Immunotherapeutics and receiving research grants from Roche and Idorsia. J.D.W. is serving as a consultant for Adaptive Biotechnologies, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage Pharma, Astellas, Bayer, BeiGene, Bristol-Myers Squibb. Celgene, Chugai, Elucida, Eli Lilly, F-Star, Genentech, Imvaq, Janssen, Kyowa Hakko Kirin, Kleo Pharmaceuticals, Linnaeus, MedImmune, Merck, Neon Therapeutics, Northern Biologics, Ono, Polaris Pharma, Polynoma, PsiOxus, PureTech, Recepta, Takara Bio, Trieza, Sellas Life Sciences, Serametrix, Surface Oncology, Syndax and Synthologic. J.D.W. received research support from Bristol-Myers Squibb, MedImmune, Merck and Genentech and has equity in Potenza Therapeutics, Tizona Pharmaceuticals, Adaptive Biotechnologies, Elucida, Imvaq, BeiGene, Trieza and Linnaeus. P.-C.H. received an honorarium from Pfizer and Chugai. J.D.W. received an honorarium from Esanex.
